Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: Pitfalls in using Rome III for functional constipation

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 3, 2011, Pages 159-163

  Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; CHRONIC IDIOPATHIC CONSTIPATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEFECATION DISORDER; DIGITAL RECTAL EXAMINATION; DISEASE CLASSIFICATION; HUMAN; IDIOPATHIC DISEASE; INTESTINE FUNCTION DISORDER; PATIENT SELECTION; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ROME III CRITERION; SYMPTOM;

EID: 80052306138     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11401773     Document Type: Editorial

References (23)

1. Andresen V. Camilleri M. Busciglio I.A. Grudell A. Burton D. McKinzie S. et al (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133: 761–768.
2. Bharucha A.E. Wald A. Enck P. Rao S. (2006) Functional anorectal disorders. Gastroenterology 130: 1510–1518.
3. Bouras E.P. Camilleri M. Burton D.D. Thomforde G. McKinzie S. Zinsmeister A.R. (2001) Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120: 354–360.
4. Camilleri M. (2010) Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 87: 748–753.
5. Camilleri M. Kerstens R. Rykx A. Vandeplassche L. (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344–2354.
6. Camilleri M. McKinzie S. Fox J. Foxx-Orenstein A. Burton D. Thomforde G. et al (2004) Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2: 895–904.
7. Chiarioni G. Whitehead W.E. Pezza V. Morelli A. Bassotti G. (2006) Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 130: 657–664.
8. Chitkara D.K. Bredenoord A.J. Cremonini F. Delgado-Aros S. Smoot R.L. El-Youssef M. et al (2004) The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation. Am J Gastroenterol 99: 1579–1584.
9. Cremonini F. Camilleri M. McKinzie S. Carlson P. Camilleri C.E. Burton D. et al (2005) Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 100: 652–663.
10. Lembo A. Camilleri M. (2003) Chronic constipation. N Engl J Med 349: 1360–1368.
11. Lembo A.J. Kurtz C.B. Macdougall J.E. Lavins B.J. Currie M.G. Fitch D.A. et al (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138: 886–895.
12. Longstreth G.F. Thompson W.G. Chey W.D. Houghton L.A. Mearin F. Spiller R.C. (2006) Functional bowel disorders. Gastroenterology 130: 1480–1491.
13. Manini M.L. Camilleri M. Goldberg M. Sweetser S. McKinzie S. Burton D. et al (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22: 42–49, e7–8.
14. Prott G. Shim L. Hansen R. Kellow J. Malcolm A. (2010) Relationships between pelvic floor symptoms and function in irritable bowel syndrome. Neurogastroenterol Motil 22: 764–769.
15. Quigley E.M. Vandeplassche L. Kerstens R. Ausma J. (2009) Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29: 315–328.
16. Rangnekar A.S. Morgan D. Knechtges P. Saad R.J. Fenner D. Morris A.M. et al (2008) Complaints suggestive of irritable bowel syndrome are common in patients with puborectalis dyssynergia: An under-recognized overlap syndrome. Gastroenterology 134: A423–A423.
17. Rao S.S.C. Tuteja A.K. Vellema T. Kempf J. Stessman M. (2004) Dyssynergic defecation: Demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 38: 680–685.
18. Rasquin A. Di Lorenzo C. Forbes D. Guiraldes E. Hyams J.S. Staiano A. et al (2006) Childhood functional gastrointestinal disorders: Child/adolescent. Gastroenterology 130: 1527–1537.
19. Surrenti E. Rath D.M. Pemberton J.H. Camilleri M. (1995) Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol 90: 1471–1475.
20. Tack J. van Outryve M. Beyens G. Kerstens R. Vandeplassche L. (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58: 357–365.
21. Talley N.J. Fleming K.C. Evans J.M. O'Keefe E.A. Weaver A.L. Zinsmeister A.R. et al (1996) Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol 91: 19–25.
22. Talley N.J. Zinsmeister A.R. van Dyke C. Melton L.J. 3rd (1991) Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101: 927–934.
23. Tantiphlachiva K. Rao P. Attaluri A. Rao S.S. (2010) Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol 8: 955–960.